Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History VRTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics VRTX

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Vertex Pharmaceuticals Inc

VRTX
Current price
468.85 USD -7.64 USD (-1.60%)
Last closed 479.53 USD
ISIN US92532F1003
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 123 287 158 784 USD
Yield for 12 month -4.48 %
1Y
3Y
5Y
10Y
15Y
VRTX
21.11.2021 - 28.11.2021

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. Address: 50 Northern Avenue, Boston, MA, United States, 02210

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

499.87 USD

P/E Ratio

Dividend Yield

Financials VRTX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures VRTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+11 020 100 000 USD

Last Year

+9 869 200 000 USD

Current Quarter

+2 770 200 000 USD

Last Quarter

+2 912 000 000 USD

Current Year

+9 489 600 000 USD

Last Year

+8 607 000 000 USD

Current Quarter

+2 407 200 000 USD

Last Quarter

+2 488 600 000 USD
EBITDA 4 584 399 872 USD
Operating Margin TTM 37.22 %
Price to Earnings
Return On Assets TTM 11.77 %
PEG Ratio 0.58
Return On Equity TTM -5.64 %
Wall Street Target Price 499.87 USD
Revenue TTM 11 099 700 224 USD
Book Value 64.20 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 3.00 %
Dividend Yield
Gross Profit TTM 5 892 899 840 USD
Earnings per share -3.83 USD
Diluted Eps TTM -3.83 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY -40.90 %
Profit Margin -8.91 %

Stock Valuation VRTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 26.81
Enterprise Value Revenue 10.67
Price Sales TTM 11.11
Enterprise Value EBITDA 254.75
Price Book MRQ 7.46

Technical Indicators VRTX

For 52 Weeks

377.85 USD 519.88 USD
50 Day MA 451.88 USD
Shares Short Prior Month 4 034 849
200 Day MA 463.46 USD
Short Ratio 2.78
Shares Short 4 389 791
Short Percent 1.77 %